Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Next phase of Covid jabs rollout starts next month

Around 26m people across England eligible for autumn booster

Wales Online

Covid vaccine plan for the very young

The government plans to buy 2.9 million doses of Covid-19 vaccine from Pfizer for children aged from six months to four years.

Bangkok Post

Covid booster rollout of dual-strain jab to start on 5 September

Moderna’s new dual-strain vaccine will be offered to millions of Britons ahead of winter

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

What's behind the FDA's controversial strategy for evaluating new COVID boosters

Some scientists are alarmed that the agency plans to evaluate the next generation of boosters by reviewing mouse studies alone. Others say there's no time to waste waiting for human trials.

WEKU

All over-50s to get a new Covid jab targeted to protect against Omicron variant

Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine

Daily Mirror

‘No second-rate vaccines’ health chief insists as half will miss out on dual-strain booster

Roughly 29 million people are eligible for an autumn booster but there are just 13 million doses of the new bivalent Moderna jab available

The Independent UK

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

No plans for UK to order more supplies of AstraZeneca Covid vaccine

JCVI says mRNA vaccines such as the Pfizer and Moderna jabs are the most effective for UK booster programme

The Guardian - UK

What we know so far about the autumn booster roll-out

It's not known how long the vaccines will offer protection for, experts have admitted

Wales Online

The U.K. approved omicron-specific booster shots. They're coming to the U.S. soon

In the U.S., officials have asked vaccine makers to target BA.5, rather than the original omicron strain. That has delayed the boosters' development — but officials hope they will be more effective.

WEKU

Government ‘confident’ people will get ‘bivalent’ jab in booster programme

The comments come after it emerged that current stock would cover only half the population eligible for the booster jab.

The Independent UK

Who is eligible to get a Covid booster jab this autumn

Some people will be offered a Moderna jab and others the Pfizer vaccine

Wales Online

Pfizer CEO tests positive for Covid

Albert Bourla has already received four doses of the Pfizer-BioNTech vaccine

The Independent UK

Pfizer CEO tests positive for COVID-19, has mild symptoms

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Edinburgh Live

Who can get a Covid vaccine booster in the UK?

The autumn booster program for Covid vaccinations will begin shortly. Over 50s, carers, frontline health workers and those at clinical risk will be inited to get a booster jab.

Daily Mirror

'Next generation' Covid vaccine that targets Omicron to be rolled out in Autumn

The groundbreaking Moderna jabs, which target both the Omicron variant and the original strain of the killer virus, will be rolled out in a bid to avoid a winter NHS nightmare

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Get all your
news in one place.

100's of premium titles.
One news app.

Dublin Live

Covid vaccine booster to be made available to more people in coming weeks

There are several ways you can book an appointments for yours

WEKU

A vaccine for Lyme disease is in its final clinical trial

There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

AAP

Pfizer's Perth employees strike over pay

Pharmaceutical giant Pfizer is facing calls to improve its pay offer to manufacturing employees in Perth, who have walked off the job.

Axios

Trial seeks to develop first Lyme disease vaccine in 2 decades

The only Lyme disease vaccine previously marketed in the U.S. was discontinued in 2002.

Benzinga

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

The Independent UK

Major test of first possible Lyme vaccine in 20 years begins

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years

1 … 42 43 44 45

People

Taweesilp Visanuyothin

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.